Lagociclovir

SKU: orb1707103

Description

Lagociclovir

Research Area

Infectious Disease & Virology

Key Properties

• CAS Number: 92562-88-4
• MW: 269.23
• Purity: 99.74%
• Formula: C₁₀H₁₂FN₅O₃
• SMILES: O=C1C2=C(N(C=N2)[C@@H]3O[C@H](CO)[C@@H](F)C3)NC(N)=N1
• Target: HBV
• Solubility: DMSO:25 mg/mL (92.86 mM)

Bioactivity

• Target IC50:
  HBV (3TC+PMEA-R):15 μM|PMEA-R (HBV):13 μM|HBV (WT):9 μM|HBV (3TC-R):8 μM
• In Vivo:
  Anti-HBV compound Oral administration of MIV-210 (20 or 60 mg/kg; body weight/day) induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following 6-week period.
• In Vitro:
  Lagociclovir (FLG) (6 days) demonstrated inhibitory activity against 3TC-R HBV, wt HBV, PMEA-R HBV, and 3TC+PMEA-R HBV in transiently transfected Huh7 cells, with IC50s of 8 ± 3.8, 9 ± 2.5, 13 ± 3.4, and 15 ± 6.8 μM, respectively . Lagociclovir (0-100 μM; 6 days) also inhibits the replication of HBV wild-type and drug-resistant mutants in transiently transfected Huh7 cells .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MIV210, MIV-210, MIV 210, Lagociclovir, HBV

Compound Identifiers

PubChem CID

135431817